Trans-Pacific AusperBio draws $120M to advance ASO for chronic HBV: Finance Report

While summer has slowed the pace of biopharma financings, this week cross-border biotech AusperBio drew a nine-digit round, Asia-to-West NewCo Sentivera launched with an immunology asset from Haisco, and Immatics announced a $173 million follow-on.

On Thursday, AusperBio Therapeutics Inc., a San Mateo, Calif.-headquartered biotech with operations in both California and China, announced a $120 million series C raise, led by an undisclosed investor. The funds will be used to advance its lead ASO therapy, AHB-137, into a Phase III trial for chronic HBV infection. ...